NuLife Sciences, Inc. Company Website:
(under construction, domain registered 10/26/16): http://www.NuLifeSciences.net OTC Markets: http://www.otcmarkets.com/stock/SMFI/profile Nevada SOS: http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=r6kBXez%252bxOtPtwfh7mJS5w%253d%253d
The NuLife Technique
With 15 years of committed research supporting the GandTex biomedical assets, NuLife will possess a unique patented proprietary method (newly branded as the "NuLife Technique") that could potentially eliminate the need for an organ or tissue match and the necessity for anti-rejection drugs in human organ transplant. With over 123K candidates waiting for an organ in the U.S. alone, the market need is significant especially considering the potential of utilizing discarded or marginal organs. Additionally, the Company's versatile technique is potentially suitable for a variety of clinical indications, including sepsis, organ failure, wound healing, and other critical health related issues that humans are challenged with today.
With the Discovery phase completed, NuLife intends to enter a preclinical phase involving animal experiments. Data derived from future clinical trials will be submitted to Federal Drug Administration (FDA), Institutional Review Boards (IRB) and/or other regulatory bodies to determine the final pathway to utilization and commercialization.
Upon regulatory approval and successful human surgeries via randomized clinical trials, NuLife plans to build a market for using discarded and marginal organs processed by the NuLife technique for transplantation. Once established and proven, NuLife will target Organ Procurement Organizations (OPO) in all 50 states who would purchase organs processed by NuLife and other centers focused on using the technique for transplantation. The Company believes that this new approach would have the potential to significantly improve the organ transplantation process by reducing the needs for matching as well as reducing the needs for dialysis for patients awaiting a donor organ. It is also expected to significantly reduce or potentially eliminate expenses and adverse events associated with anti-rejection medications. Tissue Transplantation Involving, and Tissues Modified by Decellularization And Recellularization Of Donor Tissues For Minimized Or Obviated Rejection Reactions
Decellularization and recellularization of donor tissues for minimized or obviated rejection reactions
http://patents.justia.com/inventor/james-bennie-gandy NEWS: Share Structure
| ||Market Value1 ||$4,352,012 ||a/o Oct 28, 2016 |
| ||Authorized Shares ||200,000,000 ||a/o Oct 26, 2016 |
| ||Outstanding Shares ||31,085,800 ||a/o Oct 26, 2016 |
| ||-Restricted ||8,450,000 ||a/o Oct 26, 2016 |
| ||-Unrestricted ||22,635,800 ||a/o Oct 26, 2016 |
| ||Held at DTC ||3,361,994 ||a/o Oct 26, 2016 |
| ||Float ||6,988,734 ||a/o May 08, 2015 |